|Bid||3.2000 x 900|
|Ask||3.4900 x 1800|
|Day's Range||3.2950 - 3.4447|
|52 Week Range||2.1500 - 9.1000|
|Beta (3Y Monthly)||3.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced the launch of an e-medicine platform that will enable patients with a prescription for Qsymia® (phentermine and topiramate extended-release) capsules CIV to purchase the medication online and have their orders delivered directly to their homes. The online ordering platform is another component of the Qsymia Advantage Program, which is designed to improve patient access to Qsymia. “One of the consistent pieces of feedback that we have heard from patients utilizing and physicians prescribing Qsymia has been the high out of pocket cost. Historically, the patient’s out of pocket cost has been in excess of $140 per month for the low strength doses and in excess of $200 per month for the high strength doses. These high out of pocket costs limited patients from initiating therapy or continuing therapy after initiation,” said John Amos, Chief Executive Officer at VIVUS.
“Adolescent obesity represents one of the most critical medical and public health issues not only because one out of five teenagers is affected, but also due to the fact that medical treatment options are limited,” said Aaron Kelly, PhD, Associate Professor of Pediatrics, Co-Director of the Center for Pediatric Obesity Medicine at the University of Minnesota, and an investigator on the trial. “Childhood and adolescent obesity is known to impact both physical and psychological health, and increases the risks of adult obesity, type 2 diabetes and lipid disorders,” said Santosh T. Varghese, MD, Chief Medical Officer at VIVUS.
CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc., today announced a.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., April 30, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed.
CAMPBELL, Calif., April 16, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019.
The product will be marketed in the Russian Federation under the brand name RAZATUS. "The approval of avanafil in the Russian Federation adds to the growing list of territories in which the product is now available for the treatment of ED and demonstrates the high quality capabilities of our Regulatory Affairs team, in close collaboration with our partners Sanofi and Menarini, to obtain drug approvals in multiple jurisdictions," said John Amos, Chief Executive Officer at VIVUS. "Following recent approvals of avanafil in Jordan, Saudi Arabia, Turkey and the United Arab Emirates, approval in the Russian Federation further demonstrates the potential of the product in multiple global markets.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Feb. 26, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed.
CAMPBELL, Calif., Feb. 13, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and.
Pursuant to Rule 14a‑8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders may present proper proposals for inclusion in the 2019 Proxy Statement and for consideration at the Company’s 2019 Annual Meeting. To be eligible for inclusion in the 2019 Proxy Statement, a proposal must be received by the Company no later than February 18, 2019 and must otherwise comply with Rule 14a‑8.
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
CAMPBELL, Calif., Jan. 14, 2019 -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that results from a new study evaluating the.
CAMPBELL, Calif., Dec. 27, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Nov. 01, 2018 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company.
CORAL GABLES, FL / ACCESSWIRE / September 11, 2018 / Biotech stocks continue to present key drivers of returns for many investors. Public equities have delivered strong returns underpinned by large-scale of monetary policy support. It is particularly noteworthy that the California Public Employees' Retirement System is considering the creation of a direct investment program, which would include investment in companies within sectors like healthcare and biotechnology.